Esperion Therapeutics (2) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Esperion Therapeutics has successfully transitioned from a research entity to a commercial company with two FDA-approved products: NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). Its strategy centers on maximizing the U.S. commercial potential of its oral, non-statin LDL-lowering franchise while leveraging international partnerships for global reach. The company's core achievement is establishing a new therapeutic class with a differentiated mechanism designed to avoid muscle-related side effects, targeting the vast population of patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).

Cardiovascular DiseaseMetabolic Disorders

Technology Platform

Liver-targeted ATP-citrate lyase (ACL) inhibition via a prodrug (bempedoic acid) activated specifically in the liver to lower LDL-cholesterol while designed to avoid muscle-related side effects associated with statins.

Opportunities

The recent positive cardiovascular outcomes trial (CLEAR Outcomes) data provides a transformative opportunity to expand the product label to include cardiovascular risk reduction, potentially unlocking a significantly larger patient population.

The oral, convenient profile of bempedoic acid offers a compelling alternative to injectable therapies in the large and growing market of statin-intolerant or high-risk patients.

Risk Factors

Key risks include the challenge of commercial execution against low-cost generic statins and ezetimibe, uncertainty regarding the final scope of the pending label expansion for CV risk reduction, and the potential need for future dilutive financing if revenue growth does not outpace operating expenses.

Competitive Landscape

Esperion competes in the lipid management market against generic statins, ezetimibe, and injectable PCSK9 inhibitors. Its primary competitive advantages are the oral, once-daily dosing and muscle-sparing mechanism of its approved drug, bempedoic acid, which is now supported by proven cardiovascular outcomes benefit.

More companies in Microbiome Therapeutics →More companies in United States →